The severe acute respiratory syndrome coronavirus 2 pandemic poses extraordinary
challenges. The tremendous number of coronavirus disease 2019 (COVID-19) cases in the …

The most important decision in the long-term treatment of venous thromboembolism (VTE) is
how long to anticoagulate. VTE provoked by a reversible risk factor, or a first unprovoked …

Background Pulmonary endarterectomy (PEA), pulmonary arterial hypertension (PAH)
therapy and balloon pulmonary angioplasty (BPA) are currently accepted therapies for …

Rationale: von Willebrand factor (vWF) mediates platelet adhesion during thrombosis. While
chronic thromboembolic pulmonary hypertension (CTEPH) is associated with increased …

Balloon pulmonary angioplasty (BPA) is an emerging treatment option for patients with
chronic thromboembolic pulmonary hypertension (CTEPH) who have inoperable …

Pulmonary endarterectomy is the treatment of choice for patients with operable chronic
thromboembolic pulmonary hypertension (CTEPH) as it is potentially curative. In expert …

Background Balloon pulmonary angioplasty (BPA) has been demonstrated to improve
cardiac function and exercise capacity in patients with inoperable chronic thromboembolic …

Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by recurrent or
unresolved pulmonary thromboemboli, leading to perfusion defects and increased arterial …

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and potentially life-
threatening complication of acute pulmonary embolism. It is characterised by persistent fibro …

Balloon pulmonary angioplasty continues to gain traction as a treatment option for patients
with chronic thromboembolic pulmonary disease with and without pulmonary hypertension …